By Cara Murez 

HealthDay Reporter

TUESDAY, May 23, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Monday approved a second nasal spray for reversing an opioid overdose.

To be sold as Opvee, the spray contains the medication nalmefene hydrochloride and will be available to Americans aged 12 and older with a prescription, the FDA said.

“The agency continues to advance the FDA Overdose Prevention Framework and take actionable steps that encourage harm reduction by supporting the development of novel overdose reversal products,” FDA Commissioner Dr. Robert Califf said in an agency news release.

“On the heels of the FDA’s recent approval of…


By prebo

Leave a Reply

Your email address will not be published. Required fields are marked *